Document is current
Any future updates will be listed below
-
Authors
Chilton, Caroline H. https://orcid.org/0000-0002-8076-1699
Viprey, Virginie https://orcid.org/0000-0001-6463-7092
Normington, Charmaine
Moura, Ines B. https://orcid.org/0000-0002-3019-7196
Buckley, Anthony M.
Freeman, Jane https://orcid.org/0000-0001-9580-4586
Davies, Kerrie
Wilcox, Mark H. https://orcid.org/0000-0002-4565-2868
- License Information
-
More Information
Article History
Accepted: 9 September 2025
First Online: 2 October 2025
Competing interests
: In the past 3 years, C.H.C. has received research funding from Debiopharm International and the MRC. I.B.M. has received research funding from GSK, Seres Therapeutics and the European Tissue Symposium. A.M.B. has received research funding from Seres Therapeutics. J.F. has received honorarium from Tillotts Pharma UK and grants from ACT-IVD, AJ Biosciences, Crestone, ESCMID, the MRC, the National Institute for Health and Care Research (NIHR), Pfizer and the UK Health Security Agency (UKHSA). K.D. has received honorarium from BD, Tillotts Pharma UK and Tillotts Pharma Europe, and grants from AJ Biosciences, ACT-IVD, AJ Biosciences, the MRC, the NIHR and Pfizer. M.H.W. has received consulting fees from AstraZeneca, Debiopharm, Ferring Pharmaceuticals, GSK, Nestlé, Paion, Pfizer, Phico Therapeutics, Qpex Biopharma, Seres Therapeutics, Summit, The European Tissue Symposium, Tillotts and Vedanta; lecture fees from GSK, Pfizer, Seres Therapeutics and Tillotts; and grant support from Debiopharm, GSK, Pfizer, Seres Therapeutics, Summit, the European Tissue Symposium and Tillotts. The other authors declare no competing interests.
